Status:
COMPLETED
Cell-mediated Immune Response to Influenza Vaccine
Lead Sponsor:
University of Alberta
Conditions:
Kidney Transplant
Eligibility:
All Genders
18+ years
Brief Summary
Influenza virus is an important cause of morbidity in the transplant population and can lead to viral and bacterial pneumonia. Although the annual influenza vaccine is recommended for organ transplant...
Detailed Description
There is limited prospective data on influenza infections in transplant recipients. However, influenza can be a significant cause of morbidity and mortality in some organ transplant populations. Repor...
Eligibility Criteria
Inclusion
- Adult kidney transplant recipients:
- Age ≥ 18
- Greater than 3 months post-transplant
Exclusion
- Egg allergy
- Previous life-threatening reaction to influenza vaccine (ie Guillain Barre Syndrome)
- On anticoagulants such as warfarin that precludes intramuscular injection
- Ongoing therapy for rejection
- Febrile illness in the past two weeks
- Unable to provide informed consent
- Healthy volunteers
- Inclusion Criteria:
- \- Age ≥ 18
Key Trial Info
Start Date :
November 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2010
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00677547
Start Date
November 1 2007
End Date
June 1 2010
Last Update
September 14 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G-2E1